Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.

MLA

Hulin, Cyrille, et al. “Stem Cell Yield and Transplantation in Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients Receiving Daratumumab + Bortezomib/Thalidomide/Dexamethasone in the Phase 3 CASSIOPEIA Study.” Haematologica, vol. 106, no. 8, Aug. 2021, pp. 2257–60. EBSCOhost, https://doi.org/10.3324/haematol.2020.261842.

APA

Hulin, C., Offner, F., Moreau, P., Roussel, M., Belhadj, K., Benboubker, L., Caillot, D., Facon, T., Garderet, L., Kuhnowski, F., Stoppa, A.-M., Kolb, B., Tiab, M., Jie, K.-S., Westerman, M., Lambert, J., Pei, L., Vanquickelberghe, V., De Boer, C., … Van de Donk, N. W. C. J. (2021). Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study. Haematologica, 106(8), 2257–2260. https://doi.org/10.3324/haematol.2020.261842

Chicago

Hulin, Cyrille, Fritz Offner, Philippe Moreau, Murielle Roussel, Karim Belhadj, Lotfi Benboubker, Denis Caillot, et al. 2021. “Stem Cell Yield and Transplantation in Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients Receiving Daratumumab + Bortezomib/Thalidomide/Dexamethasone in the Phase 3 CASSIOPEIA Study.” Haematologica 106 (8): 2257–60. doi:10.3324/haematol.2020.261842.